Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
TLX66 Meets Study Objectives, Holding Out in AL Amyloidosis Telix Pharmaceuticals reported the results from the TRALA trial (Targeted Radiotherapy for AL Amyloidosis), a Phase I/IIa trial evalu...
NAFLD is one of the leading causes of liver damage in the younger population. The increasing NAFLD prevalence runs parallel with the increasing trends in obesity among people. However, this does n...
EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has is...
Earlier in our article, we discussed how mostly off-label therapies so far dominate the NASH therapeutics market. So, let us dig deeper into it and find out what can we expect in the coming years ...
NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (...
With the advent of new-age healthcare industry trends that are evident as of now, there...
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...
The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...
Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...
There has been limited progress in the approval of novel agents in MDS. It has been a l...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
